DE69623325D1 - 4-hydroxycoumarin-3-carboxamide für die behandlung von nicht-insulin-abhängigen diabetes mellitus - Google Patents
4-hydroxycoumarin-3-carboxamide für die behandlung von nicht-insulin-abhängigen diabetes mellitusInfo
- Publication number
- DE69623325D1 DE69623325D1 DE69623325T DE69623325T DE69623325D1 DE 69623325 D1 DE69623325 D1 DE 69623325D1 DE 69623325 T DE69623325 T DE 69623325T DE 69623325 T DE69623325 T DE 69623325T DE 69623325 D1 DE69623325 D1 DE 69623325D1
- Authority
- DE
- Germany
- Prior art keywords
- hydroxycoumarin
- treatment
- diabetes mellitus
- carboxamides
- insulin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title 1
- OIYXGJMSOBVBQL-UHFFFAOYSA-N 4-hydroxy-2-oxochromene-3-carboxamide Chemical class C1=CC=C2OC(=O)C(C(=O)N)=C(O)C2=C1 OIYXGJMSOBVBQL-UHFFFAOYSA-N 0.000 abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/42—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4
- C07D311/56—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4 without hydrogen atoms in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
- C07F9/6552—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring
- C07F9/65522—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring condensed with carbocyclic rings or carbocyclic ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US687895P | 1995-11-17 | 1995-11-17 | |
US1997696P | 1996-06-17 | 1996-06-17 | |
PCT/US1996/017122 WO1997018808A1 (en) | 1995-11-17 | 1996-11-12 | 4-hydroxycoumarin-3-carboxamides for the treatment of diabetes mellitus |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69623325D1 true DE69623325D1 (de) | 2002-10-02 |
DE69623325T2 DE69623325T2 (de) | 2003-04-17 |
Family
ID=26676192
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69623325T Expired - Fee Related DE69623325T2 (de) | 1995-11-17 | 1996-11-12 | 4-hydroxycoumarin-3-carboxamide für die behandlung von nicht-insulin-abhängigen diabetes mellitus |
Country Status (10)
Country | Link |
---|---|
US (1) | US5723476A (de) |
EP (1) | EP0869785B1 (de) |
JP (1) | JP2000500490A (de) |
AT (1) | ATE222762T1 (de) |
AU (1) | AU7718796A (de) |
DE (1) | DE69623325T2 (de) |
DK (1) | DK0869785T3 (de) |
ES (1) | ES2181923T3 (de) |
PT (1) | PT869785E (de) |
WO (1) | WO1997018808A1 (de) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1506359A (zh) | 2002-12-05 | 2004-06-23 | �й�ҽѧ��ѧԺҩ���о��� | 新的香豆素酰胺衍生物及其制法和其药物组合物与用途 |
US20060003410A1 (en) * | 2004-06-10 | 2006-01-05 | Lee-Ming Chuang | Prostaglandin reductase |
EP1803809A3 (de) * | 2005-08-12 | 2007-12-19 | Abgenomics Corporation | Modulation des Peroxisomen-Proliferatoren-Aktivierten Rezeptors |
US20080102137A1 (en) * | 2006-10-31 | 2008-05-01 | Guffey Manning V R | Composition and method for etiological treatment and prevention of diseases and/or complications associated with chronic glucose metabolism destabilization |
AU2008209320B2 (en) * | 2007-01-25 | 2013-05-30 | NAIA Metabolic, Inc. | Insulin sensitisers and methods of treatment |
KR101133246B1 (ko) | 2010-02-24 | 2012-04-05 | 원광대학교산학협력단 | 신규한 코마린 유도체, 이의 제조방법 및 상기 코마린 유도체를 포함하는 형광 면역측정용 키트 |
WO2014061752A1 (ja) * | 2012-10-17 | 2014-04-24 | 国立大学法人岡山大学 | 化合物、その互変異性体、幾何異性体、乃至それらの塩、及びそれらの製造方法、抗菌剤、並びに感染症治療薬 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL243879A (de) * | 1958-10-01 | |||
US4078075A (en) * | 1976-09-20 | 1978-03-07 | Ciba-Geigy Corporation | Insecticidally active 3-N-(4-trifluoromethylphenyl)-carbamoyl-4-hydroxy-coumarin |
US4210667A (en) * | 1979-04-19 | 1980-07-01 | Pfizer Inc. | Pharmaceutical preparations containing coumarin carboxylic acid derivatives |
DE3613065A1 (de) * | 1986-04-18 | 1987-10-29 | Bayer Ag | Verwendung von 3-carbamoyl-4-hydroxy-cumarinen zur bekaempfung von parasitaeren helminthen, neue 3-carbamoyl-4-hydroxy-cumarine und ihre herstellung |
ATE161252T1 (de) * | 1990-09-07 | 1998-01-15 | Schering Corp | Antivirale und antihypertensive verbindungen |
EP0550493B1 (de) * | 1990-09-28 | 1995-08-09 | The Upjohn Company | Anthelmintische und coccidizide 3-carbamoyl-4-hydroxycumarine, ihre verwendung und zusammensetzungen |
EP0658158A1 (de) * | 1992-09-01 | 1995-06-21 | Pfizer Inc. | 4-hydroxy cumarin derivate mit antibacteriell wirkung |
EP0619314A1 (de) * | 1993-04-09 | 1994-10-12 | Eli Lilly And Company | 4-Phenyl-4H-Naphtho 2,1-b pyran Derivate und ihre Verwendung als Arzneimittel |
DE4337906A1 (de) * | 1993-11-08 | 1995-05-11 | Cassella Ag | Verwendung von Cumarinderivaten |
-
1996
- 1996-11-12 WO PCT/US1996/017122 patent/WO1997018808A1/en active IP Right Grant
- 1996-11-12 DE DE69623325T patent/DE69623325T2/de not_active Expired - Fee Related
- 1996-11-12 DK DK96940254T patent/DK0869785T3/da active
- 1996-11-12 ES ES96940254T patent/ES2181923T3/es not_active Expired - Lifetime
- 1996-11-12 AT AT96940254T patent/ATE222762T1/de not_active IP Right Cessation
- 1996-11-12 AU AU77187/96A patent/AU7718796A/en not_active Abandoned
- 1996-11-12 EP EP96940254A patent/EP0869785B1/de not_active Expired - Lifetime
- 1996-11-12 JP JP9519727A patent/JP2000500490A/ja not_active Withdrawn
- 1996-11-12 US US08/747,185 patent/US5723476A/en not_active Expired - Fee Related
- 1996-11-12 PT PT96940254T patent/PT869785E/pt unknown
Also Published As
Publication number | Publication date |
---|---|
PT869785E (pt) | 2002-12-31 |
DE69623325T2 (de) | 2003-04-17 |
EP0869785A1 (de) | 1998-10-14 |
EP0869785B1 (de) | 2002-08-28 |
ATE222762T1 (de) | 2002-09-15 |
WO1997018808A1 (en) | 1997-05-29 |
ES2181923T3 (es) | 2003-03-01 |
AU7718796A (en) | 1997-06-11 |
US5723476A (en) | 1998-03-03 |
JP2000500490A (ja) | 2000-01-18 |
DK0869785T3 (da) | 2002-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69822665D1 (de) | Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa-4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14-dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen | |
DE69534908D1 (de) | Verwendung von statin zur behandlung von hauterkrankungen | |
DE59409312D1 (de) | Imidazopyridine und ihre anwendung zur behandlung von magen-darm krankheiten | |
DE69626539D1 (de) | topische Verwendung von Vitamin D zur Behandlung von Augenerkrankungen | |
DE69530933D1 (de) | Verwendung von 5-(tetradecyloxy)-2-furan carbonsäure für die behandlung von alzheimer krankheit oder psychosis | |
DE60139466D1 (de) | Behandlung von diabetes | |
DK0842169T3 (da) | Benzothiophenforbindelser | |
DE69522580D1 (de) | Carboxylierte aminoguanidine zur behandlung von insulin-unabhängigem diabetes mellitus | |
FI951511A (fi) | IL-10:n käyttö insuliinista riippuvan diabetes mellituksen ennaltaestoon tai hoitoon | |
DE69623325T2 (de) | 4-hydroxycoumarin-3-carboxamide für die behandlung von nicht-insulin-abhängigen diabetes mellitus | |
DE69521138D1 (de) | Behandlung von druckbehältern | |
DE69622889T2 (de) | Substituierte 4-(1h-benzimidazol-2-yl)(1,4)diazepane für die behandlung von allergischen krankheiten | |
DE69736180D1 (de) | Behandlung von manischen erkrankungen | |
DE69606777T2 (de) | Naphthamidderivate von 3-beta-amino azabicyclooctan oder nonan als antipsychotische arzneimittel | |
NO870423L (no) | 5-substituerte oktahydroindolizin-analgetiske forbindelser og 7-keto mellomprodukter. | |
ATE107165T1 (de) | Verwendung von macrolactonen als antiallergica. | |
DE69620786D1 (de) | Verwendung von cholinesterase-inhibitoren für die herstellung eines medikaments zur behandlung von xerostomie | |
HUP0003831A2 (hu) | Szövetfaktor alkalmazása véredényképződés befolyásolására | |
DE69620394T2 (de) | Verwendung von forskolin oder diese enthaltende extrakte zur herstellung eines medikaments für die behandlung von alkoholsucht | |
DE69421705D1 (de) | Verwendung von Efaroxan und dessen Derivaten zur Herstellung eines Arzneimittels zur Behandlung neurogenerativer Erkrankungen | |
DE69832075D1 (de) | Verwendung von eprosartan zur behandlung von isoliertem systolischem bluthochdrucks | |
ATE432709T1 (de) | Behandlung von diabetes | |
ATE275627T1 (de) | Menschlicher site-1 protease-spezifischer promotor | |
DE68906028D1 (de) | Verwendung von acetyl-d-carnitin zur therapeutischen behandlung von glaukom. | |
DE69619048D1 (de) | Verwendung von Oligosacchariden, welche die Adhäsion an Lewis-x Glycolipid hemmen, zur Herstellung eines Medikaments für die Behandlung von Katarakt |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |